Loading
Led the EORTC/NCIC trial that made temozolomide with radiotherapy the glioblastoma standard, and the EF-14 trial of tumour treating fields.
Roger Stupp is Professor of Neurological Surgery and Neurology at Northwestern University in Chicago, having previously worked in Lausanne and with the EORTC. His specialisms are neuro-oncology, glioblastoma and tumour treating fields. He led the EORTC 26981/NCIC CE.3 trial, reported in the New England Journal of Medicine as radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, which defined the Stupp protocol that remains the glioblastoma standard. He also led EF-14, the JAMA trial that added tumour treating fields to maintenance temozolomide, the basis for the Optune device. His publications are listed on PubMed.
Shares Robot-placed catheters and live imaging for drug infusion into brain tumours, EORTC 26981 / NCIC CE.3 (Stupp trial), Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma, EORTC.
Shares EORTC 26981 / NCIC CE.3 (Stupp trial), Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma, Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne, Glioma & glioblastoma.
Shares EORTC 26981 / NCIC CE.3 (Stupp trial), Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma, Glioma & glioblastoma.
Shares EF-14, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
Shares Stupp 2005: temozolomide added to radiotherapy for newly diagnosed glioblastoma, EORTC.
Shares Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
Shares Optune / Optune Pax (TTFields), Tumour treating fields (TTFields).
Shares EORTC, Temozolomide, Glioma & glioblastoma.